CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 84 enrolled
Drug / intervention
TrueTear +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03325673
NCT03325673N/ACompleted

Randomized, Double-arm, Controlled Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control (CORIANDER)

Allergan·interventional·Posted Oct 30, 2017·Updated Dec 18, 2019

In Brief

A clinical study evaluating TrueTear and TrueTear Sham Control for Dry Eye Syndromes. Completed, enrolled 84 participants across 1 site.

Detailed Summary

This study will evaluate the increase in comfort and comfortable contact lens (CL) wear time associated with application of TrueTear (active intranasal neurostimulation) compared with application of TrueTear sham control (intranasal application which is not electrically active) in symptomatic CL wearers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 30, 2017
Enrollment StartNov 22, 2017
Primary CompletionNov 29, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.7 years ago

Interventions

TrueTeardevice

TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.

TrueTear Sham Controldevice

TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.